Sphera Funds Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$26.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$11.5M |
| 3 |
BridgeBio Pharma
BBIO
|
+$9.97M |
| 4 |
Cellebrite
CLBT
|
+$9.52M |
| 5 |
Palo Alto Networks
PANW
|
+$8.87M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Annexon
ANNX
|
+$6.61M |
| 2 |
SolarEdge
SEDG
|
+$5.4M |
| 3 |
Oric Pharmaceuticals
ORIC
|
+$5.3M |
| 4 |
ATXS
Astria Therapeutics
ATXS
|
+$4.66M |
| 5 |
Dyne Therapeutics
DYN
|
+$4.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.06% |
| 2 | Technology | 14.11% |
| 3 | Utilities | 1.21% |
| 4 | Consumer Discretionary | 1.06% |
| 5 | Industrials | 0.44% |
No holdings matched the selected filter criteria.
Similar funds
Sphera Funds Management's Q1 2026 Portfolio in Review
As of Q1 2026, Sphera Funds Management held 120 positions worth $630M, up 22% from $517M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sphera Funds Management deployed $86.5M of net new capital in Q1 2026, opening 21 new positions and adding to 31 existing holdings. Its largest new stake was Cellebrite: 631,521 shares worth $8.7M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 80% a quarter earlier, followed by Technology and Utilities.
On the sell side, the largest reduction was SolarEdge, an estimated $5.4M trimmed.
- Sphera Funds Management's largest Q1 2026 buy was Cellebrite: 631,521 shares worth $8.7M.
- Sphera Funds Management added most to Mineralys Therapeutics in Q1 2026, an estimated $26.1M increase.
- Sphera Funds Management's biggest Q1 2026 reduction was SolarEdge, cutting an estimated $5.4M.
- Sphera Funds Management fully exited Annexon in Q1 2026, selling an estimated $6.61M.
- Sphera Funds Management's ten largest holdings make up 37% of its $630M portfolio in Q1 2026.
- Sphera Funds Management opened 21 new positions and closed 24 in Q1 2026.
- Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $630M.
Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.